XML 37 R14.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Accounts Payable and Accrued Liabilities | 6 Months Ended
--- | ---
Jun. 30, 2024
Payables and Accruals [Abstract] |
Accounts Payable and Accrued Liabilities | 8. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consist of the following (in thousands):
| As of
| June 30, 2024 |  | December 31, 2023
Accounts payable and other accrued operating expenses | $ | 51,363 |  |  | $ | 65,393 |
Accrued clinical trial expenses | 22,581 |  |  | 23,711 |
Accrued professional fees | 16,114 |  |  | 13,885 |
Accrued technical operation expenses | 11,097 |  |  | 9,187 |
Accrued compensation and employee related costs | 42,198 |  |  | 48,933 |
Accrued royalty and milestones payable | 7,288 |  |  | 5,674 |
Accrued interest payable | 2,175 |  |  | 2,175 |
Revenue Interest Payments payable | 3,613 |  |  | 3,347 |
Accrued sales allowances and related costs | 14,479 |  |  | 10,937 |
Accrued France ATU reimbursement payable | 17,188 |  |  | 14,685 |
Deferred and contingent consideration | 81,600 |  |  | 6,700 |
Accrued milestone payment to AstraZeneca | 12,500 |  |  | — |
Other accrued liabilities | 8,648 |  |  | 10,360 |
| $ | 290,844 |  |  | $ | 214,987 |
In May 2024, a $12.5 million milestone commitment became payable to AstraZeneca upon the Company's release of an official public statement that it intends to file a new drug application (NDA) for brensocatib.

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration